179 related articles for article (PubMed ID: 7564501)
1. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines.
Berman E; McBride M; Tong W
Leukemia; 1994 Jul; 8(7):1191-6. PubMed ID: 8035611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
6. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
7. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
10. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
11. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
12. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
Berman E; Adams M; Duigou-Osterndorf R; Godfrey L; Clarkson B; Andreeff M
Blood; 1991 Feb; 77(4):818-25. PubMed ID: 1993221
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
15. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Dorr R; Karanes C; Spier C; Grogan T; Greer J; Moore J; Weinberger B; Schiller G; Pearce T; Litchman M; Dalton W; Roe D; List AF
J Clin Oncol; 2001 Mar; 19(6):1589-99. PubMed ID: 11250987
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
18. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
20. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]